Loading clinical trials...

Safety and Efficacy of Remote Ischemic Conditioning Treatment for Community-based Essential Hypertension | Clinical Trials | Clareo Health

UNKNOWNNA

Safety and Efficacy of Remote Ischemic Conditioning Treatment for Community-based Essential Hypertension

Safety and Efficacy of Remote Ischemic Conditioning Treatment for Community-based Essential Hypertension: a Randomized, Parallel-controlled Clinical Trial

NCT03945305•Yi Yang

View on ClinicalTrials.gov

Summary

The purpose of this study is to explore the efficacy and safety of remote ischemic conditioning for essential hypertension in the community population.

Detailed Description

At present, stroke has become the leading cause of death in China, with hypertension being the primary risk factor and one of the controllable risk factors. Current studies have shown that remote ischemic conditioning can improve vascular endothelial function, inhibit sympathetic nervous system activity and regulate immune and inflammatory reactions. Thus it may exert anti-hypertensive effects through multiple mechanisms. The purpose of this study is to investigate the efficacy and safety of remote ischemic conditioning for essential hypertension in the community population.

Eligibility

Age

40 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Age≥40 years, ≤ 75 years, regardless of sex;
•2. Having the history of essential hypertension and the systolic blood pressure of at least 140 mm Hg on two consective days;
•3. Signed and dated informed consent is obtained

Exclusion Criteria

•1. Blood pressure ≥ 180/110mmHg;
•2. Planned adjustment of antihypertensive drugs in the next month;
•3. Severe hematologic disorders or significant coagulation abnormalities;
•4. Individuals who had contraindication of remote ischemic conditioning, such as severe soft tissue injury, fracture or vascular injury in the upper limb, acute or subacute venous thrombosis, arterial occlusive disease, subclavian steal syndrome, etc;
•5. Pregnant or lactating women;
•6. Severe hepatic and renal dysfunction, or ALT/AST \>3 times upper limit of normal, or serum creatinine \>265umol/l (\>3mg/dl);
•7. Patients being enrolled or having been enrolled in another clinical trial within the 3 months prior to this clinical trial;
•8. Patients unsuitable for enrollment in the clinical trial according to the investigator's discretion.

Locations (1)

First Hospital of Jilin University

Changchun, Jilin, China

Key Dates

Start Date

November 1, 2023

Primary Completion Date

March 31, 2024

Completion Date

April 28, 2024

Last Updated

February 28, 2024

Enrollment

500

ESTIMATED participants

Conditions

Essential Hypertension

Interventions

Patients are treated with previous antihypertensive treatment plus remote ischemic conditioning.

DEVICE

Previous antihypertensive treatment

OTHER

Contacts

Yi Yang, MD,PhD

CONTACT

0086-13756661217 doctor_yangyi@163.com

Zhen-Ni Guo, MD

CONTACT

zhen1ni2@163.com

Study of KK3910 in Healthy Volunteers and Patients With Essential Hypertension

NCT06823947

Healthy Volunteers Essential Hypertension

View study

ACTIVE_NOT_RECRUITING

Effectiveness of Entresto (Sacubitril/Valsartan) in Japanese Patients With Hypertension

NCT06604897

Essential Hypertension

View study

COMPLETEDPHASE3

PHASE III, RANDOMIZED, ACTIVE-COMPARATOR CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF NIFEDIPINE 30MG EXTENDED-RELEASE IN ADULT PATIENTS DIAGNOSED WITH MILD OR MODERATE HYPERTENSION IN COLOMBIA.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 28, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Safety and Efficacy of Remote Ischemic Conditioning Treatment for Community-based Essential Hypertension

Inclusion Criteria

Exclusion Criteria

Study of KK3910 in Healthy Volunteers and Patients With Essential Hypertension

Effectiveness of Entresto (Sacubitril/Valsartan) in Japanese Patients With Hypertension

PHASE III, RANDOMIZED, ACTIVE-COMPARATOR CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF NIFEDIPINE 30MG EXTENDED-RELEASE IN ADULT PATIENTS DIAGNOSED WITH MILD OR MODERATE HYPERTENSION IN COLOMBIA.

Mat Pilates With Paced Breathing Versus Diaphragmatic Breathing in Stage II Hypertension

A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-1 and BR1015-2 Under Fed Conditions

A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-3 and BR1015-2 Under Fed Conditions